Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down on Analyst Downgrade

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) gapped down prior to trading on Thursday after Jefferies Financial Group lowered their price target on the stock from $550.00 to $549.00. The stock had previously closed at $481.59, but opened at $450.00. Jefferies Financial Group currently has a buy rating on the stock. Alnylam Pharmaceuticals shares last traded at $453.0810, with a volume of 441,911 shares changing hands.

Several other research analysts also recently commented on ALNY. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a report on Monday, October 13th. Bank of America boosted their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. UBS Group boosted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Finally, Royal Bank Of Canada boosted their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $473.79.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares in the company, valued at approximately $362,390. This trade represents a 95.87% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ALNY. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $662,837,000. Holocene Advisors LP acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $194,616,000. Orbis Allan Gray Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $162,577,000. Finally, Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after purchasing an additional 323,206 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

The firm has a market cap of $58.93 billion, a price-to-earnings ratio of -182.01 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a 50 day moving average of $460.16 and a 200 day moving average of $367.47.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.39 by $0.45. The business had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $943.37 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue was up 149.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.